Inhibikase Therapeutics, Inc. $IKT Stake Boosted by Sands Capital Alternatives LLC

Sands Capital Alternatives LLC increased its stake in Inhibikase Therapeutics, Inc. (NASDAQ:IKT) by 18.9% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 13,018,965 shares of the company’s stock after buying an additional 2,068,965 shares during the quarter. Inhibikase Therapeutics accounts for approximately 5.1% of Sands Capital Alternatives LLC’s portfolio, making the stock its 4th largest holding. Sands Capital Alternatives LLC owned 17.32% of Inhibikase Therapeutics worth $26,689,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. ADAR1 Capital Management LLC lifted its holdings in Inhibikase Therapeutics by 2.5% during the third quarter. ADAR1 Capital Management LLC now owns 5,247,603 shares of the company’s stock valued at $8,501,000 after purchasing an additional 125,498 shares during the last quarter. Nantahala Capital Management LLC lifted its holdings in Inhibikase Therapeutics by 79.4% during the fourth quarter. Nantahala Capital Management LLC now owns 3,929,292 shares of the company’s stock valued at $8,055,000 after purchasing an additional 1,739,292 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Inhibikase Therapeutics by 1.5% during the third quarter. Vanguard Group Inc. now owns 3,273,339 shares of the company’s stock valued at $5,303,000 after purchasing an additional 48,969 shares during the last quarter. Kalehua Capital Management LLC purchased a new stake in Inhibikase Therapeutics during the fourth quarter valued at about $3,588,000. Finally, Geode Capital Management LLC lifted its holdings in Inhibikase Therapeutics by 1.4% during the fourth quarter. Geode Capital Management LLC now owns 1,128,239 shares of the company’s stock valued at $2,313,000 after purchasing an additional 15,665 shares during the last quarter. 3.81% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have commented on IKT shares. Oppenheimer started coverage on shares of Inhibikase Therapeutics in a report on Wednesday, June 10th. They set an “outperform” rating and a $5.00 price objective on the stock. LADENBURG THALM/SH SH started coverage on shares of Inhibikase Therapeutics in a report on Wednesday, March 4th. They set a “buy” rating and a $4.00 price objective on the stock. Lifesci Capital raised shares of Inhibikase Therapeutics to a “strong-buy” rating in a report on Monday, February 23rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inhibikase Therapeutics in a report on Tuesday, April 21st. Four analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $5.40.

Inhibikase Therapeutics Price Performance

Shares of IKT opened at $1.67 on Monday. The business’s 50-day moving average price is $1.77 and its 200-day moving average price is $1.75. Inhibikase Therapeutics, Inc. has a twelve month low of $1.33 and a twelve month high of $2.26. The stock has a market cap of $220.49 million, a PE ratio of -3.88 and a beta of 0.93.

Inhibikase Therapeutics (NASDAQ:IKT) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.10) earnings per share for the quarter, meeting the consensus estimate of ($0.10). Analysts expect that Inhibikase Therapeutics, Inc. will post -0.4 earnings per share for the current fiscal year.

Inhibikase Therapeutics Profile

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.